Old Web
English
Sign In
Acemap
>
authorDetail
>
Jørn S. Jakobsen
Jørn S. Jakobsen
Ferring Pharmaceuticals
Medicine
Bladder cancer
Testosterone
Clinical endpoint
Degarelix
3
Papers
7
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance
2021
Molecular Therapy - Oncolytics
Jennifer Green
Robin Osterhout
Amy Klova
Carsten Merkwirth
Scott Rp McDonnell
Reza Beheshti Zavareh
Bryan C. Fuchs
Adeela Kamal
Jørn S. Jakobsen
Show All
Source
Cite
Save
Citations (0)
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics
2021
Frontiers in Oncology
Jan P. Bogen
Julius Grzeschik
Jørn S. Jakobsen
Alexandra Bähre
Björn Hock
Harald Kolmar
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
2019
Asian Journal of Urology
Yinghao Sun
Liping Xie
Tao Xu
Jørn S. Jakobsen
Weiqing Han
P. Sørensen
Xiao-Feng Wang
Show All
Source
Cite
Save
Citations (7)
1